Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis.
Background: End Stage Renal disease (ESRD) as it was historically termed is a term that encompasses all degrees of decreased renal function, from damaged–at risk through mild, moderate, and severe chronic kidney failure. ESRD is a worldwide public health problem. In the United States, there is a ris...
Main Authors: | , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Albanian Society for Trauma and Emergency Surgery
2018-07-01
|
Series: | Albanian Journal of Trauma and Emergency Surgery |
Subjects: | |
Online Access: | http://journal.astes.org.al/index.php/AJTES/article/view/15 |
id |
doaj-9ffe6ca05e8b41c09b23de0a4b3b8900 |
---|---|
record_format |
Article |
spelling |
doaj-9ffe6ca05e8b41c09b23de0a4b3b89002020-11-24T22:01:16ZengAlbanian Society for Trauma and Emergency SurgeryAlbanian Journal of Trauma and Emergency Surgery2521-87782616-49222018-07-012210.32391/ajtes.v2i2.1515Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis.Lutfi Zylbeari0Kastriot Haxhirexha1Nasir Behxheti2Ferizate Dika Haxhirexha3Gazmend Zylbeari4Zamira Bexheti5Jetnire Jakupi Alimani6Sihana Lika Ahmeti7Arbnore Qalili8Hanife Lika9State University of Tetova, Medical Faculty, Tetova, MacedoniaState University of Tetova, Medical Faculty, Tetova, MacedoniaState University of Tetova, Medical Faculty, Tetova, MacedoniaState University of Tetova, Medical Faculty, Tetova, MacedoniaState University of Tetova, Medical Faculty, Tetova, MacedoniaState University of Tetova, Medical Faculty, Tetova, MacedoniaPrivate Special Hospital for Nephrology and Hemodialysis "Vita Medical Group" - Tetova, MacedoniaPrivate Special Hospital for Nephrology and Hemodialysis "Vita Medical Group" - Tetova, MacedoniaPrivate Special Hospital for Nephrology and Hemodialysis "Vita Medical Group" - Tetova, MacedoniaPrivate Special Hospital for Nephrology and Hemodialysis "Vita Medical Group" - Tetova, MacedoniaBackground: End Stage Renal disease (ESRD) as it was historically termed is a term that encompasses all degrees of decreased renal function, from damaged–at risk through mild, moderate, and severe chronic kidney failure. ESRD is a worldwide public health problem. In the United States, there is a rising incidence and prevalence of kidney failure, with poor outcomes and high cost (see Epidemiology). Material and Methods: The blood sample for routine analysis (lipidogram) and specific analysis was taken at 08o'clock in the morning with the room temperature that variated from 19 to 24°C, before the hemodialysis session, minimum 12 hours of fasting - with tendency to avoid the absorption effect of food by the intestine as well as avoid absorption of lipids and formation of chilomicrones. In all samples regardless of their group, the concentration of ApoC-II and lipids were analyzed in a period of 12 months in a period of 12 months (the measurements were made every three months, it means we totally made 3 measurements in 9 months). Results: The results from patients and controlling group for Apo-C3 and lipid profile (ChT, TG, HDL-ch, LDL-ch) are given in table number 3. A significant statistical difference with p<0.0001 is found from the results of the lipidic profile and ApoC-III of patients with ESRD treated with HD compared with the results of the controlling group for the same parameters. Conclusion: In this study patients with ESRD treated with HD have high parameters of ApoC-III, TG, LDL-ch but low concentrations of HDL-ch due to impaired catabolism of apolipoproteins in this specific group of patients. In all patients symptoms of CDV (myocardial infarction, angina pectoris, ischemia), acute coronary syndrome were noticed.http://journal.astes.org.al/index.php/AJTES/article/view/15apolypoprotein-C3 (Apo-C3)end stage renal disease |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lutfi Zylbeari Kastriot Haxhirexha Nasir Behxheti Ferizate Dika Haxhirexha Gazmend Zylbeari Zamira Bexheti Jetnire Jakupi Alimani Sihana Lika Ahmeti Arbnore Qalili Hanife Lika |
spellingShingle |
Lutfi Zylbeari Kastriot Haxhirexha Nasir Behxheti Ferizate Dika Haxhirexha Gazmend Zylbeari Zamira Bexheti Jetnire Jakupi Alimani Sihana Lika Ahmeti Arbnore Qalili Hanife Lika Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis. Albanian Journal of Trauma and Emergency Surgery apolypoprotein-C3 (Apo-C3) end stage renal disease |
author_facet |
Lutfi Zylbeari Kastriot Haxhirexha Nasir Behxheti Ferizate Dika Haxhirexha Gazmend Zylbeari Zamira Bexheti Jetnire Jakupi Alimani Sihana Lika Ahmeti Arbnore Qalili Hanife Lika |
author_sort |
Lutfi Zylbeari |
title |
Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis. |
title_short |
Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis. |
title_full |
Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis. |
title_fullStr |
Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis. |
title_full_unstemmed |
Apolipoprotein c-iii (apo-c3) Metabolism in Patients with End Stage Renal Disease Treated with Long Term Hemodialysis. |
title_sort |
apolipoprotein c-iii (apo-c3) metabolism in patients with end stage renal disease treated with long term hemodialysis. |
publisher |
Albanian Society for Trauma and Emergency Surgery |
series |
Albanian Journal of Trauma and Emergency Surgery |
issn |
2521-8778 2616-4922 |
publishDate |
2018-07-01 |
description |
Background: End Stage Renal disease (ESRD) as it was historically termed is a term that encompasses all degrees of decreased renal function, from damaged–at risk through mild, moderate, and severe chronic kidney failure. ESRD is a worldwide public health problem. In the United States, there is a rising incidence and prevalence of kidney failure, with poor outcomes and high cost (see Epidemiology).
Material and Methods: The blood sample for routine analysis (lipidogram) and specific analysis was taken at 08o'clock in the morning with the room temperature that variated from 19 to 24°C, before the hemodialysis session, minimum 12 hours of fasting - with tendency to avoid the absorption effect of food by the intestine as well as avoid absorption of lipids and formation of chilomicrones. In all samples regardless of their group, the concentration of ApoC-II and lipids were analyzed in a period of 12 months in a period of 12 months (the measurements were made every three months, it means we totally made 3 measurements in 9 months).
Results: The results from patients and controlling group for Apo-C3 and lipid profile (ChT, TG, HDL-ch, LDL-ch) are given in table number 3. A significant statistical difference with p<0.0001 is found from the results of the lipidic profile and ApoC-III of patients with ESRD treated with HD compared with the results of the controlling group for the same parameters.
Conclusion: In this study patients with ESRD treated with HD have high parameters of ApoC-III, TG, LDL-ch but low concentrations of HDL-ch due to impaired catabolism of apolipoproteins in this specific group of patients. In all patients symptoms of CDV (myocardial infarction, angina pectoris, ischemia), acute coronary syndrome were noticed. |
topic |
apolypoprotein-C3 (Apo-C3) end stage renal disease |
url |
http://journal.astes.org.al/index.php/AJTES/article/view/15 |
work_keys_str_mv |
AT lutfizylbeari apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT kastriothaxhirexha apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT nasirbehxheti apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT ferizatedikahaxhirexha apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT gazmendzylbeari apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT zamirabexheti apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT jetnirejakupialimani apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT sihanalikaahmeti apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT arbnoreqalili apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis AT hanifelika apolipoproteinciiiapoc3metabolisminpatientswithendstagerenaldiseasetreatedwithlongtermhemodialysis |
_version_ |
1725840546679750656 |